PRECIGEN, INC.

PGEN ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item Jun 2022 Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021 Dec 2020 Sep 2020
Revenue $2.9M $5.5M $-17.4M $3.3M $3.8M $24.5M $19.3M $23.6M
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development
SG&A Expense
Operating Income $-26.1M $-24.0M $-31.7M $-26.4M $-31.0M $-21.9M $-35.2M $-23.0M
Operating Margin -898.2% -434.5% 182.2% -791.5% -812.6% -89.3% -181.9% -97.6%
Interest Expense
Pretax Income $-26.1M $-24.0M $-31.7M $-26.4M $-31.0M $-21.9M $-40.3M $-27.6M
Income Tax Expense $-89.0K $-58.0K
Net Income $-17.6M $-19.3M $-25.0M $-29.8M $-20.1M $-17.3M $-41.7M $-29.5M
Net Margin -605.8% -349.2% 143.9% -893.0% -525.6% -70.7% -215.5% -125.1%
EPS (Basic) $-0.09 $-0.10 $-0.13 $-0.15 $-0.10 $-0.09 $-0.23 $-0.18
EPS (Diluted) $-0.09 $-0.10 $-0.13 $-0.15 $-0.10 $-0.09 $-0.23 $-0.18
Shares Outstanding (Basic) 200.5M 199.6M 197.8M 199.2M 199.0M 193.5M 167.1M 165.5M
Shares Outstanding (Diluted) 200.5M 199.6M 197.8M 199.2M 199.0M 193.5M 167.1M 165.5M
Dividends Per Share
← Newer Page 2 of 7 Older →